Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence

Abstract

This study showed long-term persistence of anti-TBEV NT antibodies for up to 10 years after the first booster dose of TBEvac in all age groups, regardless of the primary vaccination schedule.

Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules

“…8 Of note, over 10 years of follow-up post-boosting, no consistent decline in geometric mean NT titers was observed within the same age groups, although smaller overall values were observed for participants receiving the booster dose at 50-59 and ≥60 years of age than at 15-49 years of age. 8 However, the comparison was hindered by a relatively small sample size for the ≥60-year age group, which also applied for our analysis. Therefore, analyses were not performed by age stratum.…”

“…7 Of these, 201 individuals who had received one of the licensed vaccination schedules were followed up in the second extension study (NCT01562444) from year 6 to 10 post-booster dose. 8 The current analysis was conducted using individual anti-TBEV NT titers of adolescents and adults vaccinated with one of the three prime-boost vaccination schedules, measured once a year, for up to 10 years following the booster dose. All available data from participants in each of the primary and extension studies were used.…”

“…4 The polygeline-free inactivated TBE vaccine (Encepur Adults, GSK), targeting the European subtype, is licensed in Europe for use in adults and adolescents ≥12 years of age and has been shown to be immunogenic and well tolerated, 5,6 with persistently high antibody titers induced up to 10 years following a first booster vaccination. 7,8 The TBE vaccine has also been reported to induce antibodies against various Asian TBEV isolates. 4,9 Although there is no established correlate of protection against TBE, the World Health Organization supports the use of a surrogate marker of protection represented by the presence of circulating antibodies against TBEV at or above a locally agreed concentration considered as clinically meaningful.…”

“…8,13 A recent study demonstrated that ≥90% of individuals vaccinated with the TBE vaccine maintained NT titers ≥10 up to 10 years after a first booster dose, regardless of age and primary vaccination schedule received. 8 Moreover, no TBE infections occurred during this period. 8 With the aim of estimating the evolution of the immune response over time beyond available clinical data, we modeled anti-TBEV NT antibody levels up to 20 years post-first boosting following primary vaccination with one of the 3 licensed schedules.…”

Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis

“…[13][14][15] The vaccine efficacy was assumed to last 10 years after the fourth dose in children and 5 years in the adult cohorts. [26,27] Both vaccines available in Sweden are considered equal immunogenic and interchangeable. [28]…”